Cempra, Inc. (CEMP)
(Delayed Data from NSDQ)
$2.33 USD
+0.03 (1.09%)
Updated Nov 3, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Melinta Therapeutics, Inc. [CEMP]
Reports for Purchase
Showing records 41 - 60 ( 89 total )
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Transferring Coverage
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Risk in the Rear View, EV $629M Offers Compelling Entry Point
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Bears Firmly in Control of the Solithromycin Narrative
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Well-Positioned as Pharma Pricing Strategies Go Under the Microscope
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Expecting <8 Month Review For Solithromycin
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Managing Expectations Heading into Solitaire-IV Readout
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D